Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-25T04:02:00.298Z Has data issue: false hasContentIssue false

Efficiency of Cationic Rosette Nanotubes for siRNA Delivery

Published online by Cambridge University Press:  02 March 2011

Aws Alshamsan
Affiliation:
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia National Institute for Nanotechnology (NINT-NRC), Edmonton, AB, Canada
Mounir EL Bakkari
Affiliation:
National Institute for Nanotechnology (NINT-NRC), Edmonton, AB, Canada Department of Chemistry, Faculty of Science, University of Alberta, Edmonton, AB, Canada
Hicham Fenniri
Affiliation:
National Institute for Nanotechnology (NINT-NRC), Edmonton, AB, Canada Department of Chemistry, Faculty of Science, University of Alberta, Edmonton, AB, Canada
Get access

Abstract

Cationic rosette nanotubes (RNTs) were generated by functionalization of selfcomplementary twin guanine-cytosine (G^C) motifs with up to 15 L-lysine residues (Kn.T, n = 1–15). siRNA binding capacity was determined by gel retardation assay on agarose gel. Up to K5.T, siRNA complexation was a function of oligolysine-chain length and mole ratio of Kn.T. At higher Kn.T, local cationic density employed by supramolecular assembly emerged as a contributor to siRNA complexation. We have shown that no effective siRNA binding was achieved with equivalent mole ratios of corresponding oligolysine peptides (not conjugated to the G∧C motif). With K12.T, siRNA complexation gave spherical structures in the range of 200 nm, which was internalized and retained by human cell lines without noticeable cytotoxicity. In this report, we demonstrate for the first time the capacity of the RNTs as siRNA carriers that can be tailored to achieve maximum siRNA loading efficiency without carrier-associated cell toxicity. We anticipate these cationic RNTs to be effective in the delivery of biologicallyfunctional siRNA.

Type
Research Article
Copyright
Copyright © Materials Research Society 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Ameyar-Zazoua, M., Guasconi, V. and Ait-Si-Ali, S., Expert Opin Biol Ther 5, 221–4 (2005).Google Scholar
2. Caplen, N. J. and Mousses, S., Ann N Y Acad Sci 1002, 56–62 (2003).Google Scholar
3. Schutze, N., Mol Cell Endocrinol 213, 115–9 (2004).Google Scholar
4. Tang, N., Trends Biochem Sci 30, 106–14 (2005).Google Scholar
5. Hede, K., J Natl Cancer Inst 97, 626–8 (2005).Google Scholar
6. Dev, K. K., IDrugs 9, 279–82 (2006).Google Scholar
7. Alshamsan, A., Haddadi, A., Incani, V., Samuel, J., Lavasanifar, A., Uludağ, H., Mol Pharm 6 121–33 (2009).Google Scholar
8. Cao, G., Nanostructures and Nanomaterials: Synthesis, Properties and Applications (Imperical College Press, London, UK, 2004).Google Scholar
9. Hughes, G. A., Nanomedicine 1, 22–30 (2005).Google Scholar
10. Fenniri, H., Mathivanan, P., Vidale, K. L., Sherman, D. M., Hallenga, K. and Wood, K. V., Stowell, J. G., J Am Chem Soc 123 3854–5 (2001).Google Scholar
11. Fenniri, H., Deng, B. L., Ribbe, A. E., J Am Chem Soc 124 11064–72 (2002).Google Scholar
12. Fenniri, H., Deng, B. L., Ribbe, A. E., Hallenga, K., Jacob, J. and Thiyagarajan, P., Proc Natl Acad Sci U S A 99 6487–92 (2002).Google Scholar
13. Moralez, J.G., Raez, J., Yamazaki, T., Motkuri, R. K., Kovalenko, A. and Fenniri, H., J Am Chem Soc 127 8307–9 (2005).Google Scholar